Application of gene therapy on squamous cell carcinoma of the head and neck (SCCHN)

根据最近的荟萃分析，化疗已被证明对提高头颈部鳞状细胞癌(SCCHN)患者的生存率是有益的。顺铂是治疗SCCHN的标准化疗药物。因此，顺铂耐药是提高生存率的主要障碍之一。首先建立了顺铂耐药的SCCHN细胞系。另一方面，我们还证明了以转化生长因子-α为靶点的反义基因传递能有效地抑制小细胞肺癌的体内生长。这一次，我们成功地证明了在局部注射转化生长因子-α作为载体的同时，局部注射顺铂增强了顺铂对小细胞肺癌的抗肿瘤作用。该动物设计为顺铂耐药的SCCHN的治疗提供了良好的临床前模型。

According to recent meta-analyses, chemotherapy has been proved to be beneficial in improving survival for the patients with squamous cell carcinoma of the head and neck (SCCHN). Cisplatin is the standard chemotherapeutic agent in treating SCCHN patients. Therefore cisplatin resistant is one of the major obstacles in improving survival. At first we established cisplatin-resistant SCCHN cell lines. Then we developed animal model where subcutaneously inoculated SCCHN tumor progresses even with cisplatin administration which were weekly injected intra-peritoneally (IP).On the other hand, we have also shown that antisense (AS) gene delivery targeting transforming growth factor (TGF)-α was effective in suppressing SCCHN tumor growth in vivo.This time we succeeded to show the results where simultaneous administration of TGF-α AS plasmid vector injected topically enhanced anti-tumor effects of cisplatin on SCCHN in vivo. This animal design provides a good preclinical model for the treatment of cisplatin-resistant SCCHN.